The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
The ALLEGORY study demonstrated statistically significant improvements in key measures, including British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
Furthering cell therapy ambition across oncology and autoimmune diseases
A total of three targets have been selected for portfolio entry in the collaboration to date, with the potential to generate further future development milestones and sales-based royalty revenues for BenevolentAI
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
